# China Pharma Holdings, Inc.: filings

CPHI · NYSE · CIK 1106644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cphi.md) · [Financials](/companies/cphi/financials.md) · [Filings](/companies/cphi/filings.md) · [Insiders](/companies/cphi/insiders.md)

## Reports and events: 162 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 56, 10-Q 53, CORRESP 22, 10-K 18, UPLOAD 17, DEF 14A 16, 10-Q/A 15, 4 10, DEFA14A 10, SC 13G/A 10, 3 6, PRE 14A 6, SC 13G 6, 424B3 5, 10-K/A 4, EFFECT 4, PRE 14C 4, 424B5 3, DEF 14C 3, S-3 3, PRER14C 2, S-8 2, 10KSB/A 1, 8-A12B 1, CERTNYS 1, D 1, DEFA14C 1, DEFR14C 1, NT 10-K 1, POS AM 1, S-3/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-14 | 16:32 ET | [10-Q](/filings/0001213900-26-090173.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090173 |
| 2026-07-22 | 17:26 ET | [8-K](/filings/0001213900-26-080475.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-080475 |
| 2026-05-15 | 16:05 ET | [10-Q](/filings/0001213900-26-057705.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057705 |
| 2026-04-01 | 16:15 ET | [10-K](/filings/0001213900-26-038521.md) | Annual report, period 2025-12-31 | 0001213900-26-038521 |
| 2026-03-03 | 16:05 ET | [8-K](/filings/0001213900-26-023022.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-023022 |
| 2026-02-10 | 16:49 ET | [8-K](/filings/0001213900-26-014338.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-014338 |
| 2026-01-06 | 16:05 ET | [8-K](/filings/0001213900-26-001785.md) | 5.07 Shareholder vote results | 0001213900-26-001785 |
| 2025-12-23 | 16:05 ET | [8-K](/filings/0001213900-25-125299.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-25-125299 |
| 2025-12-10 | 16:49 ET | [8-K](/filings/0001213900-25-120129.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-25-120129 |
| 2025-11-14 | 16:22 ET | [DEF 14A](/filings/0001213900-25-110882.md) | Proxy statement, period 2025-12-30 | 0001213900-25-110882 |
| 2025-11-12 | 16:10 ET | [10-Q](/filings/0001213900-25-109203.md) | Quarterly report, period 2025-09-30 | 0001213900-25-109203 |
| 2025-08-14 | 16:06 ET | [10-Q](/filings/0001213900-25-076642.md) | Quarterly report, period 2025-06-30 | 0001213900-25-076642 |
| 2025-05-14 | 16:20 ET | [10-Q](/filings/0001213900-25-043334.md) | Quarterly report, period 2025-03-31 | 0001213900-25-043334 |
| 2025-04-04 | 16:05 ET | [8-K](/filings/0001213900-25-029000.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-029000 |
| 2025-03-31 | 16:20 ET | [10-K](/filings/0001213900-25-026280.md) | Annual report, period 2024-12-31 | 0001213900-25-026280 |
| 2024-12-26 | 16:30 ET | [8-K](/filings/0001213900-24-112685.md) | 1.02 Termination of a material agreement | 0001213900-24-112685 |
| 2024-12-26 | 16:05 ET | [8-K](/filings/0001213900-24-112658.md) | 5.07 Shareholder vote results | 0001213900-24-112658 |
| 2024-12-13 | 08:20 ET | [8-K](/filings/0001213900-24-108617.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-24-108617 |
| 2024-11-13 | 16:05 ET | [10-Q](/filings/0001213900-24-097461.md) | Quarterly report, period 2024-09-30 | 0001213900-24-097461 |
| 2024-11-12 | 16:05 ET | [DEF 14A](/filings/0001213900-24-096780.md) | Proxy statement, period 2024-12-22 | 0001213900-24-096780 |
| 2024-08-14 | 16:05 ET | [10-Q](/filings/0001213900-24-068984.md) | Quarterly report, period 2024-06-30 | 0001213900-24-068984 |
| 2024-05-30 | 16:05 ET | [8-K](/filings/0001213900-24-047965.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-24-047965 |
| 2024-05-15 | 16:06 ET | [10-Q](/filings/0001213900-24-043591.md) | Quarterly report, period 2024-03-31 | 0001213900-24-043591 |
| 2024-05-08 | 16:05 ET | [8-K](/filings/0001213900-24-040851.md) | 4.01 Change of auditor | 0001213900-24-040851 |
| 2024-04-01 | 16:06 ET | [10-K](/filings/0001213900-24-028731.md) | Annual report, period 2023-12-31 | 0001213900-24-028731 |
| 2024-03-29 | 16:05 ET | [8-K](/filings/0001213900-24-027972.md) | 8.01 Other events | 0001213900-24-027972 |
| 2024-02-23 | 16:05 ET | [8-K](/filings/0001213900-24-016507.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-24-016507 |
| 2024-02-08 | 16:05 ET | [8-K](/filings/0001213900-24-011587.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-24-011587 |
| 2023-12-21 | 16:05 ET | [8-K](/filings/0001213900-23-097680.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity | 0001213900-23-097680 |
| 2023-12-19 | 16:05 ET | [8-K](/filings/0001213900-23-096920.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001213900-23-096920 |
| 2023-11-13 | 16:05 ET | [10-Q](/filings/0001213900-23-086100.md) | Quarterly report, period 2023-09-30 | 0001213900-23-086100 |
| 2023-11-07 | 16:05 ET | [DEF 14A](/filings/0001213900-23-084279.md) | Proxy statement, period 2023-12-18 | 0001213900-23-084279 |
| 2023-10-03 | 16:05 ET | [8-K](/filings/0001013762-23-001101.md) | 3.01 Delisting notice | 0001013762-23-001101 |
| 2023-08-14 | 15:40 ET | [10-Q](/filings/0001213900-23-066936.md) | Quarterly report, period 2023-06-30 | 0001213900-23-066936 |
| 2023-05-12 | 16:06 ET | [10-Q](/filings/0001213900-23-039007.md) | Quarterly report, period 2023-03-31 | 0001213900-23-039007 |
| 2023-04-20 | 16:05 ET | [8-K](/filings/0001213900-23-031309.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-23-031309 |
| 2023-03-30 | 16:54 ET | [10-K](/filings/0001213900-23-024710.md) | Annual report, period 2022-12-31 | 0001213900-23-024710 |
| 2023-03-29 | 16:05 ET | [8-K](/filings/0001213900-23-024081.md) | 8.01 Other events | 0001213900-23-024081 |
| 2023-02-24 | 16:05 ET | [8-K](/filings/0001213900-23-014316.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-23-014316 |
| 2022-12-30 | 16:05 ET | [8-K](/filings/0001213900-22-084016.md) | 5.07 Shareholder vote results | 0001213900-22-084016 |
| 2022-12-02 | 17:00 ET | [8-K](/filings/0001213900-22-077369.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-22-077369 |
| 2022-12-02 | 16:10 ET | [8-K](/filings/0001213900-22-077304.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-22-077304 |
| 2022-11-14 | 16:58 ET | [DEF 14A](/filings/0001213900-22-072361.md) | Proxy statement, period 2022-12-28 | 0001213900-22-072361 |
| 2022-11-14 | 16:09 ET | [10-Q](/filings/0001213900-22-072200.md) | Quarterly report, period 2022-09-30 | 0001213900-22-072200 |
| 2022-09-30 | 16:15 ET | [8-K](/filings/0001213900-22-060675.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-22-060675 |
| 2022-08-11 | 16:05 ET | [10-Q](/filings/0001213900-22-046859.md) | Quarterly report, period 2022-06-30 | 0001213900-22-046859 |
| 2022-06-22 | 16:05 ET | [8-K](/filings/0001213900-22-034328.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-22-034328 |
| 2022-05-12 | 16:06 ET | [10-Q](/filings/0001213900-22-025938.md) | Quarterly report, period 2022-03-31 | 0001213900-22-025938 |
| 2022-03-30 | 16:06 ET | [10-K](/filings/0001213900-22-016151.md) | Annual report, period 2021-12-31 | 0001213900-22-016151 |
| 2021-12-29 | 16:00 ET | [8-K](/filings/0001213900-21-067912.md) | 5.07 Shareholder vote results | 0001213900-21-067912 |

Page 1 of 4. [Older](/companies/cphi/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:51 ET. No prices; not investment advice.